Faecalibacterium Prausnitzii Composition for Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively prevent or treat cognitive decline and maintain/improve brain function, particularly in conditions like Alzheimer's disease and mild cognitive impairment, despite the recognized influence of gut microbiota on brain health.
Innovation Solution
Identification and utilization of specific gut microorganisms, particularly Faecalibacterium prausnitzii strains with unique DNA sequences, to improve cognitive function and develop compositions and evaluation methods for dementia diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to treat cognitive decline, then current treatment options are available, but effective prevention and treatment of cognitive deterioration cannot be achieved
Solution Approach 1:
The patent introduces gut microbiota as an intermediary substance that mediates between the gut and brain through the gut-brain axis. Specific bacteria strains (Faecalibacterium prausnitzii, Bacteroides fragilis, and their components) act as mediators to transmit beneficial signals to the brain, reducing inflammation and amyloid-β accumulation, thereby effectively preventing and treating cognitive deterioration without using conventional neurodegenerative drugs.
2Adaptability or versatility
If gut microbiota is considered to influence brain function, then new treatment directions are opened, but specific effective microorganisms and mechanisms remain unidentified
Solution Approach 1:
The patent extracts and identifies specific effective microorganisms from the complex gut microbiota. Through comparative analysis of gut microbiota between healthy individuals and AD/MCI patients, the invention isolates and characterizes specific strains (Faecalibacterium prausnitzii with accession number NITE BP-03169, Bacteroides fragilis with accession number NITE BP-03170) and their functional components, providing precise identification and characterization of the beneficial microbes.
Solution Approach 2:
The patent applies parameter changes by analyzing and comparing quantitative parameters of gut microbiota composition. Through statistical analysis of microbial abundance, diversity, and composition parameters between control and disease groups, the invention identifies significant differences in microbial profiles that correlate with cognitive function, enabling precise characterization of beneficial microbial states.
3Reliability
If Faecalibacterium prausnitzii is administered to improve cognitive function, then cognitive deterioration is prevented, but the mechanism of action and optimal dosage remain to be fully elucidated
Solution Approach 1:
The patent segments the complex mechanism of action into distinct functional components. It separates and identifies specific bacterial components (cell wall components, metabolic products, and other functional substances) responsible for different effects. The invention also divides the mechanism into upstream (gut microbiota modulation) and downstream (brain inflammation reduction, amyloid-β clearance) effects, making the complex pathway manageable and optimizable.
Data Source
AI summary
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.